A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke

An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.

[1]  R. Jordan,et al.  Fractionation of low molecular weight heparin species and their interaction with antithrombin. , 1979, The Journal of biological chemistry.

[2]  U. Lindahl,et al.  Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. , 1980, Thrombosis research.

[3]  J. Hirsh,et al.  Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. , 1981, Thrombosis research.

[4]  D. Tollefsen,et al.  Detection of a new heparin-dependent inhibitor of thrombin in human plasma. , 1981, The Journal of clinical investigation.

[5]  J. Hirsh,et al.  Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction. , 1982, Thrombosis research.

[6]  F. Schwarz,et al.  TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS BY NEW HEPARINOID , 1983, The Lancet.

[7]  H. Cate,et al.  USE OF A NEW HEPARINOID AS ANTICOAGULANT DURING ACUTE HAEMODIALYSIS OF PATIENTS WITH BLEEDING COMPLICATIONS , 1983, The Lancet.

[8]  H. Büller,et al.  Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease , 1984, Annals of neurology.

[9]  J. Hirsh,et al.  Rationale Behind the Development of Low Molecular Weight Heparin Derivatives , 1985, Seminars in thrombosis and hemostasis.

[10]  D. Hoppensteadt,et al.  Studies on the Antithrombotic Effects and Pharmacokinetics of Heparin Fractions and Fragments , 1985, Seminars in thrombosis and hemostasis.

[11]  J. Sage.  Stroke. The use and overuse of heparin in therapeutic trials. , 1985, Archives of neurology.

[12]  C. Prowse,et al.  The Measurement of Heparin and Other Therapeutic Sufphated Polysaccharides in Plasma, Serum and Urine , 1985, Thrombosis and Haemostasis.

[13]  H. Adams,et al.  A dose-escalation study of large doses of naloxone for treatment of patients with acute cerebral ischemia. , 1986, Stroke.

[14]  J. Hirsh,et al.  DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE , 1987, The Lancet.